DGAP-News: Eckert & Ziegler Q3 / 2017: Continually high income. Net liquidity exceeds EUR 50 million.

Nachricht vom 09.11.2017 (www.4investors.de) -


DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results

Eckert & Ziegler Q3 / 2017: Continually high income. Net liquidity exceeds EUR 50 million.
09.11.2017 / 07:45


The issuer is solely responsible for the content of this announcement.
Press ReleaseEckert & Ziegler Q3 / 2017: Continually high income. Net liquidity exceeds EUR 50 million.

Berlin, 09 November 2017. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a Berlin-based company specializing in isotope technology for medical, scientific and industrial applications, increased its earnings per share by 63% to EUR 2.32 in the first nine months compared with the prior year's period. The main reasons for the sales increase were stable growth in the Devices division of the Radiopharma segment and the first sales generated by the Gamma-Service Group acquired at the end of May. Excluding the discontinued operations and therewith according to the requirements under IFRS 5, earnings per share rose to EUR 1.72, increasing compared with the prior year's quarter by EUR 0.22 per share or 14.7 %.

At EUR 100.4 million, Group sales were 12 % above the prior year's level of EUR 89.5 million at the end of the third quarter of 2017. The main reasons for the sales increase were stable growth in the Devices division of the Radiopharma segment and the first sales generated by the Gamma-Service Group acquired at the end of May. Currency effects had no impact on sales. Organic, real sales growth - in other words, sales adjusted for currency effects and excluding the acquisitions and disposals made in 2016 and 2017 - came to EUR 5.4 million. Excluding the adjustments required under IFRS 5, the Group recorded total sales of EUR 106.6 million in the third quarter of 2017, compared with EUR 103.1 million in the prior year's period.

The Radiopharma segment continues to be the growth driver. If the discontinued Cyclotron division is excluded, year-on-year growth was EUR 5.0 million or 32 %. In the USA in particular, the company further increased its year-on-year sales. Sales in the Radiation Therapy segment rose by EUR 0.4 million or 3% to EUR 18.3 million. The newly acquired Gamma-Service Group is included in the Isotope Products segment. The sales generated by the products and services of the newly acquired companies played a key part in enabling this segment to also increase its year-on-year sales by EUR 5.5 million or 9 % to EUR 63.7 million.

Cash flow increased faster than earnings, causing net liquidity - in other words, cash and cash equivalents less total liabilities to banks - to rise by EUR 25.3 million to EUR 50.2 million.

As a result of the extraordinary income from the sale of the Cyclotron division, earnings of around EUR 2.80 per share are forecast for 2017, EUR 0.60 of which is due to extraordinary effects and discontinued operations. Sales of approximately EUR 140 million are expected.

The complete financial statements can be viewed here:http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz317e.pdf

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), with approximately 760 employees, is one the world's largest providers of isotope technology for radiation therapy and nuclear medicine.Contributing to saving lives.
For further information or questions, please contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com












09.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
Eckert & Ziegler Strahlen- und Medizintechnik AG

Robert-Rössle-Str.10

13125 Berlin


Germany
Phone:
49 30 941084-138
Fax:
49 30 941084-112
E-mail:
karolin.riehle@ezag.de
Internet:
www.ezag.de
ISIN:
DE0005659700
WKN:
565970
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News
DGAP News Service




626549  09.11.2017 









Aktuelle Nachrichten aus der 4investors-Redaktion

21.06.2018 - capsensixx: Keine Zeichnungsgewinne beim Börsenstart
21.06.2018 - Paion: Frisches Geld aus Frankreich
21.06.2018 - Aovo Touristik: Überraschendes Ergebnis
21.06.2018 - Publity: Gewinnwarnung
21.06.2018 - mVise: Götz bestätigt Prognose
21.06.2018 - FCR Immobilien: Zukäufe in Stuhr und Freital
21.06.2018 - UET United Electronic Technology. Verkauf bringt Sonderertrag
21.06.2018 - Einhell: Neue Jahresprognose
21.06.2018 - Semper idem Underberg: Sehr ungewöhnliche Kommunikationspolitik
21.06.2018 - Nanogate erhöht die finanzielle Flexibilität


Chartanalysen

21.06.2018 - JinkoSolar Aktie: Das wird spannend!
21.06.2018 - Deutsche Bank Aktie: Das sieht übel aus, aber…
21.06.2018 - Siemens Healthineers Aktie: Neue Kaufsignale - die Rallye geht weiter
21.06.2018 - Evotec Aktie: Alles läuft auf eine Entscheidung hinaus!
21.06.2018 - Medigene Aktie: Nimmt die Erholung jetzt Fahrt auf?
21.06.2018 - Heidelberger Druck Aktie: Wenn alles gut geht...
21.06.2018 - BYD Aktie: Schlechte Nachrichten!
20.06.2018 - Heidelberger Druck Aktie: Lichtblick am Mittwochmorgen, aber…
20.06.2018 - Dialog Semiconductor Aktie: Ein entscheidender Tag?
20.06.2018 - Geely Aktie: Diese Marke hat es in sich!


Analystenschätzungen

21.06.2018 - Dialog Semiconductor: Abwärtstrend setzt sich fort
21.06.2018 - Daimler: Doppelte Abstufung nach der Warnung
21.06.2018 - Daimler: Analysten reagieren gelassen auf Gewinnwarnung
20.06.2018 - artec: Aktie mit neuem Kursziel
20.06.2018 - ThyssenKrupp: Positive Auswirkungen
20.06.2018 - K+S: Aktie weiter mit Kaufvotum
20.06.2018 - Volkswagen: Überraschende Entwicklung
20.06.2018 - Continental: Kommt ein Börsengang?
20.06.2018 - Roche: Sinnvolle Übernahme
20.06.2018 - Dialog Semiconductor: Apple-Abhängigkeit kann kleiner werden


Kolumnen

21.06.2018 - Gold: Es kriselt trotz Krise... - Donner + Reuschel Kolumne
21.06.2018 - Keine Zinserhöhung der Bank of England erwartet - Commerzbank Kolumne
21.06.2018 - DAX 30 kämpft mit wichtiger Hürde - Donner + Reuschel Kolumne
21.06.2018 - SAP Aktie: In luftigen Höhen - UBS Kolumne
21.06.2018 - DAX: Doppelhoch droht aktiviert zu werden - UBS Kolumne
20.06.2018 - DAX 30 kurz vor wichtiger Hürde: Kaufsignal 200-Tage-Linie!? - Donner + Reuschel Kolumne
20.06.2018 - USA: Baugenehmigungen sinken im Mai, die Baubeginne steigen aber - Commerzbank Kolumne
20.06.2018 - EuroStoxx 50: Rallychance vertan - UBS Kolumne
20.06.2018 - DAX: Richtungsentscheidung sollte bald fallen - UBS Kolumne
18.06.2018 - DAX: „Dribbling“ auf der 13.000 - Wichtiger Test zum Wochenstart - Donner + Reuschel Kolumne

All Right Reserved by minimalthemes - ©2018 Stoffels & Barck GbR